| Literature DB >> 25548439 |
Christoph Busemann1, Susanne Klein1, Christian Andreas Schmidt1, Matthias Evert2, Gottfried Dölken1, William H Krüger1.
Abstract
Prognosis of peripheral and other advanced T cell lymphomas is poor. 20 patients with a median age of 46.4 (range 20.5-64.1) years were treated with autoSCT (n = 6) or alloSCT (n = 14) from 1996 to 2013. All patients were at high risk either due to the IPI-score or to the fact that SCT was part of a salvage therapy. Conditioning prior to alloSCT was myeloablative in seven cases (50 %). The patients were pretreated with 8.5 (median, range 2-38) cycles of chemotherapy. Ten patients are alive in CR after a median follow-up of 1.3 years (range 0.1-13.3). OS was 53 % after one and 40 % after 10 years. Best survival was reached after related alloSCT (80 % at 10 years) compared to other modalities. GvHD did not influence survival. AlloSCT from related donors can cure patients from T-cell lymphomas. Unrelated alloSCT or high-dose therapy and autoSCT are an option for patients without a familiar donor.Entities:
Keywords: Allogeneic stem cell transplantation; Autologous stem cell transplantation; Graft versus lymphoma effects; T-cell derived non-Hodgkin’s lymphoma
Year: 2014 PMID： 25548439 PMCID： PMC4275534 DOI： 10.1007/s12288-014-0398-9
Source DB: PubMed Journal: Indian J Hematol Blood Transfus ISSN： 0971-4502 Impact factor: 0.900